decisionhealth Newsletters, Coder Pink Sheets - 2009 Issue 7 (July)
Prostate cancer drugs: Some LCDs say patients may pay the difference
Subscribe or sign in to view the full article.
Article Overview
This article covers Medicare local coverage determination policy for prostate cancer drug therapy, focusing on least costly alternative payment rules, contractor variation, and billing considerations for practices that administer LHRH-related treatments. It is relevant to urology practices, coding and reimbursement staff, and clinicians who need to understand how Medicare administrative contractor guidance may affect claim payment and patient cost-sharing. The article also discusses historical context around one drug’s reimbursement and related policy developments.
Why This Topic Matters
Coverage and payment policies for prostate cancer therapies can change how claims are billed and how much a patient may owe. Practices need to understand contractor guidance, documentation expectations, and which Medicare policies apply in their jurisdiction.
Article Sections
-
Medicare LCD policy for least costly alternatives
Introduces a local coverage policy affecting prostate cancer drug reimbursement and describes the general least costly alternative concept in Medicare contractor guidance.
-
Drug options, HCPCS codes, and Medicare fees
Lists the prostate cancer drug options discussed in the article along with their billing identifiers and general fee context for the time period covered.
-
Billing the patient when a higher-cost drug is chosen
Explains the article’s discussion of contractor policies, patient notices, and claim payment considerations when a more expensive therapy is used.
-
Transition to MAC status and jurisdiction changes
Notes that contractors were reissuing related coverage policies during the move to Medicare Administrative Contractor status and that jurisdiction changes were underway.
-
Lupron reimbursement history
Summarizes the article’s background discussion of reimbursement scrutiny, prior government actions, and broader policy history involving one of the therapies mentioned.
What You Will Learn
- How Medicare contractor policy can affect payment for prostate cancer drug therapy
- Why least costly alternative coverage matters for billing and patient responsibility
- What general reimbursement and documentation issues practices should watch for when contractor policies change
- How historical payment scrutiny has influenced the broader reimbursement environment for these therapies
Who Should Read This
- Urology practices
- Medical coders
- Billing staff
- Reimbursement specialists
- Practice managers
- Compliance staff
Codes Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com